These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 8679448)
61. Comparison of the performance of guaiac-based and two immunochemical fecal occult blood tests for identifying advanced colorectal neoplasia in Taiwan. Ou CH; Kuo FC; Hsu WH; Lu CY; Yu FJ; Kuo CH; Wang JY; Wu MT; Shiea J; Wu DC; Hu HM J Dig Dis; 2013 Sep; 14(9):474-83. PubMed ID: 23701988 [TBL] [Abstract][Full Text] [Related]
62. A population-based comparison of immunochemical fecal occult blood tests for colorectal cancer screening. Raginel T; Puvinel J; Ferrand O; Bouvier V; Levillain R; Ruiz A; Lantieri O; Launoy G; Guittet L Gastroenterology; 2013 May; 144(5):918-25. PubMed ID: 23376426 [TBL] [Abstract][Full Text] [Related]
63. Cost-effectiveness of screening for colorectal cancer in France using a guaiac test versus an immunochemical test. Lejeune C; Dancourt V; Arveux P; Bonithon-Kopp C; Faivre J Int J Technol Assess Health Care; 2010 Jan; 26(1):40-7. PubMed ID: 20059779 [TBL] [Abstract][Full Text] [Related]
64. Chemical and immunological testing for faecal occult blood in screening subjects at risk of familial colorectal cancer. Hunt LM; Rooney PS; Bostock K; Robinson MH; Hardcastle JD; Armitage NC Gut; 1997 Jan; 40(1):110-2. PubMed ID: 9155586 [TBL] [Abstract][Full Text] [Related]
65. Colorectal cancer screening: why immunochemical faecal occult blood test performs as well with either one or two samples. Guittet L; Bouvier V; Guillaume E; Levillain R; Ruiz A; Lantieri O; Launoy G Dig Liver Dis; 2012 Aug; 44(8):694-9. PubMed ID: 22525156 [TBL] [Abstract][Full Text] [Related]
66. Effect of rehydration on guaiac-based faecal occult blood testing in colorectal cancer screening. Castiglione G; Biagini M; Barchielli A; Grazzini G; Mazzotta A; Salvadori P; Scillone L; Ciatto S Br J Cancer; 1993 May; 67(5):1142-4. PubMed ID: 8494714 [TBL] [Abstract][Full Text] [Related]
67. Interference of plant peroxidases with guaiac-based fecal occult blood tests is avoidable. Sinatra MA; St John DJ; Young GP Clin Chem; 1999 Jan; 45(1):123-6. PubMed ID: 9895348 [TBL] [Abstract][Full Text] [Related]
68. Colorectal cancer screening by guaiac faecal occult blood test in France: Evaluation of the programme two years after launching. Leuraud K; Jezewski-Serra D; Viguier J; Salines E Cancer Epidemiol; 2013 Dec; 37(6):959-67. PubMed ID: 24035240 [TBL] [Abstract][Full Text] [Related]
69. Systematic review with meta-analysis: faecal occult blood tests show lower colorectal cancer detection rates in the proximal colon in colonoscopy-verified diagnostic studies. Hirai HW; Tsoi KK; Chan JY; Wong SH; Ching JY; Wong MC; Wu JC; Chan FK; Sung JJ; Ng SC Aliment Pharmacol Ther; 2016 Apr; 43(7):755-64. PubMed ID: 26858128 [TBL] [Abstract][Full Text] [Related]
70. Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. Ahlquist DA; Wieand HS; Moertel CG; McGill DB; Loprinzi CL; O'Connell MJ; Mailliard JA; Gerstner JB; Pandya K; Ellefson RD JAMA; 1993 Mar; 269(10):1262-7. PubMed ID: 8437303 [TBL] [Abstract][Full Text] [Related]
71. Fecal occult blood testing: clinical value and limitations. Simon JB Gastroenterologist; 1998 Mar; 6(1):66-78. PubMed ID: 9531118 [TBL] [Abstract][Full Text] [Related]
72. Participation in four rounds of a French colorectal cancer screening programme with guaiac faecal occult blood test: a population-based open cohort study. Denis B; Gendre I; Perrin P J Med Screen; 2015 Jun; 22(2):76-82. PubMed ID: 25576338 [TBL] [Abstract][Full Text] [Related]
73. Replacing guaiac-based tests with immunochemical tests in colorectal cancer screening. Schlackman N Am J Med; 2003 Aug; 115(2):154; author reply 154-5. PubMed ID: 12893403 [No Abstract] [Full Text] [Related]
74. Screening for colorectal cancer: comparison of perceived test burden of guaiac-based faecal occult blood test, faecal immunochemical test and flexible sigmoidoscopy. Hol L; de Jonge V; van Leerdam ME; van Ballegooijen M; Looman CW; van Vuuren AJ; Reijerink JC; Habbema JD; Essink-Bot ML; Kuipers EJ Eur J Cancer; 2010 Jul; 46(11):2059-66. PubMed ID: 20621736 [TBL] [Abstract][Full Text] [Related]
75. Immunochemical faecal occult blood test: number of samples and positivity cutoff. What is the best strategy for colorectal cancer screening? Grazzini G; Visioli CB; Zorzi M; Ciatto S; Banovich F; Bonanomi AG; Bortoli A; Castiglione G; Cazzola L; Confortini M; Mantellini P; Rubeca T; Zappa M Br J Cancer; 2009 Jan; 100(2):259-65. PubMed ID: 19142185 [TBL] [Abstract][Full Text] [Related]
76. Fecal occult blood tests. A cost-effectiveness analysis. Gyrd-Hansen D Int J Technol Assess Health Care; 1998; 14(2):290-301. PubMed ID: 9611904 [TBL] [Abstract][Full Text] [Related]
77. Screening for colorectal cancer with an immunological faecal occult blood test: 2-year follow-up. Robinson MH; Marks CG; Farrands PA; Bostock K; Hardcastle JD Br J Surg; 1996 Apr; 83(4):500-1. PubMed ID: 8665240 [TBL] [Abstract][Full Text] [Related]
78. Screening for colorectal cancer with immunochemical faecal occult blood tests. Faivre J; Dancourt V; Lejeune C Dig Liver Dis; 2012 Dec; 44(12):967-73. PubMed ID: 22898146 [TBL] [Abstract][Full Text] [Related]
79. A case-control study evaluating occult blood screening for colorectal cancer with hemoccult test and an immunochemical hemagglutination test. Saito H; Soma Y; Nakajima M; Koeda J; Kawaguchi H; Kakizaki R; Chiba R; Aisawa T; Munakata A Oncol Rep; 2000; 7(4):815-9. PubMed ID: 10854550 [TBL] [Abstract][Full Text] [Related]